NCT07479979 2026-03-18
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
Phase 1/2 Not yet recruiting
Clinical Trials
7 trialsNCT07172412 2025-09-30
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06900088 2025-03-28
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT06813079 2025-02-18
Using Tumor Models to Determine Treatments
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT06613035 2024-09-25
Twice-per-weekSelinexor, 2 Days Melphalan
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting
NCT06573138 2024-08-27
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06573151 2024-08-27
Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
Ruijin Hospital
Phase 2 Not yet recruiting